Preventive medecine & genetics

Visual identity, video production & graphics: Ines Kedjem

  • Prof. Suzette Delaloge

Dr. Suzette Delaloge’s presentation aims to translate advances in genetics into large-scale personalized cancer prevention strategies.
In response to rising cancer-related costs and treatment-focused models, she advocates a shift toward targeted prevention and early detection.
High-impact variants such as BRCA1/2, PALB2, and TP53 provide a strong scientific foundation, supported by established clinical guidelines.

Prophylactic surgery has demonstrated significant reductions in cancer incidence and mortality.
Polygenic risk scores enable more refined risk stratification in the general population.
Prospective trials such as WISDOM and MyPeBS are evaluating risk-stratified screening approaches across Europe.
Genetics must be combined with exposome analysis, biomarkers, imaging, and artificial intelligence.
Personalized prevention requires structured digital tools and coordinated hospital–community care pathways.
Key challenges include professional acceptance, health equity, training, and ethical considerations.
This vision supports a paradigm shift toward predictive, preventive, and personalized oncology at the public health level.

Preventive medicine and genetics: the example of nephrogenomics, from research to clinical practice

Visual identity, video production & graphics: Ines Kedjem

  • Prof. Laurent Mesnard

Professor Laurent Mesnard’s presentation highlights the integration of genomics into preventive medicine for kidney diseases.
Nephrogenomics enhances the understanding of disease origins, improves diagnosis, and enables personalized treatment strategies.
Chronic kidney disease affects around three million people in France, including 80,000 with end-stage renal failure.

A significant proportion of these conditions have a genetic basis or remain without an identified cause.
Genomic analysis could improve up to 30% of diagnoses, particularly in unexplained nephropathies.
Sequencing technologies, including whole exome and whole genome sequencing, provide a 20–25% diagnostic yield in rare kidney diseases.
Genetic diagnosis supports tailored treatments, optimized transplantation decisions, and family screening.
Early integration into care pathways improves clinical outcomes and reduces diagnostic costs.
Nephrogenomics paves the way for predictive medicine, helping slow progression toward dialysis.
Its future development relies on data sharing and the integration of polygenic risk scores and targeted therapies.